Articles tagged with Chemotherapy
Researchers discover a drug that inhibits TAK-1 enzyme, making pancreatic cancer cells sensitive to chemotherapy. The combination of the drug with classic anti-cancer drugs shows significant tumor reduction and increased survival rates in mice.
A phase I extension study has shown that 64% of patients with the BRAF mutation experienced partial response to a new compound, with rapid and dramatic shrinking of metastatic tumours. The treatment has fewer side effects compared to standard chemotherapy and is being explored as part of larger trials.
A Purdue University researcher developed a fiber-optic sensor capable of measuring oxygen intake rates in real-time. The self-referencing optrode has broad applications across disciplines, including biomedical science, agriculture, and material science.
A new study found that targeted heat therapy significantly improves overall survival and reduces cancer recurrence in patients with locally advanced soft tissue sarcomas. The treatment, which involves heating the tumor to kill cancer cells, also makes chemotherapy more effective and improves blood flow.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
A randomized phase III study found that pemetrexed significantly improved progression-free survival (4.3 months vs 2.6 months) and overall survival (13.4 months vs 10.6 months) compared to placebo in patients with advanced non-squamous NSCLC who did not progress after initial platinum-based chemotherapy.
A new once-daily medication has shown to be as effective as multiple dosings for treating the most common mouth infection in HIV/AIDS patients. The treatment, a small tablet applied daily, provides relief from oral candidiasis (OC) with few or no side effects.
A new treatment protocol using dexamethasone instead of prednisone and less intensive chemotherapy showed similar event-free survival in non-high risk patients but better results in high-risk patients, reducing the risk of side effects. Overall, the treatment strategy improved survival rates for children with acute lymphoblastic leukemia.
American mayapple, a common weed in US, contains high podophyllotoxin levels, offering potential for commercial production of anti-cancer compound. Researchers identify eastern US colonies with high podophyllotoxin content, paving the way for development of high-value crop.
A Phase II study shows Avastin significantly increases response rates, progression-free survival times and survival rates in patients with recurrent glioblastoma. The treatment was found to be effective both alone and in combination with chemotherapy, improving patient outcomes and quality of life.
A new tumor marker has been identified for brain tumor resistance, allowing for targeted therapy approaches. The discovery of a
A study found that chemotherapy impairs sleep-wake activity rhythms in breast cancer patients, leading to shorter days and disrupted biological clocks. The disruption worsens with repeated chemotherapy cycles, highlighting the need for routine screening and management of sleep disturbances.
Researchers found that nadroparin almost halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy. The study, published in The Lancet Oncology, showed a significant reduction in thromboembolic events in patients treated with nadroparin compared to those receiving placebo.
Researchers at University of Utah Health have made a surprising connection between high levels of GSTM4 protein and poor chemotherapy response in Ewing's sarcoma patients. The study suggests that targeting GSTM4 could lead to more effective treatments for individual patients.
Researchers found that a key protein called Fbx6 helps eliminate activated Chk1, but defects in this process can lead to chemotherapy resistance. By understanding how cancer cells respond to Chk1 degradation, scientists may develop new treatments with fewer side effects.
A research team led by Professor Patrick Gunning at the University of Toronto has developed molecules that inhibit Stat3, a protein involved in almost all cancers. These inhibitors show selectivity against cancer cells but not healthy cells, offering potential for improved chemotherapy efficacy and reduced side effects.
Scientists at Dana-Farber Cancer Institute have discovered the mechanism behind a DNA repair-blocking approach to cancer treatment, suggesting that these drugs can sensitize cancer cells to chemotherapy. The findings also indicate that normal cells may be protected from DNA damage by these inhibitors.
New research by MIT cancer biologists shows that tumor mutations can predict chemotherapy success. Genetic profiling of tumors can help doctors tailor treatments to each patient. The study identified specific genes and their interactions to determine how well cancer cells respond to chemotherapy.
New commentary published in JNCI Journal of the National Cancer Institute discusses treatment options for metastatic breast cancer. The European School of Oncology Metastatic Breast Cancer Task Force recommends sequential chemotherapy with a single agent for patients without rapid progression or life-threatening metastasis.
Researchers found that combination therapies tailored to patient prognosis improved patient outcomes and increased five-year, disease-free survival rates. Prophylactic cranial irradiation was shown to significantly decrease the risk for brain metastases in NSCLC patients.
Studies presented at the WCLC confirm that targeted therapies have improved efficacy and prolonged progression-free survival time compared to chemotherapy. Patients with EGFR mutations who received gefitinib experienced longer progression-free survival and greater objective response rates, while erlotinib showed prolonged progression-f...
A novel immunoconjugate targeting EphA2 protein shows substantial antitumor activity in ovarian cancer cell lines and mice. The agent inhibits tumor growth by 85% compared to control, with significant effects on proliferation and apoptosis.
Researchers developed a novel therapeutic delivery system that targets EphA2 protein in ovarian cancer cells, delivering chemotherapy with high specificity and reducing tumor growth by up to 98%. The therapy shows promising results in preclinical models and is expected to enter phase I clinical trials soon.
Researchers from Université de Montréal and McGill University have engineered an enzyme that resists harmful agents like methotrexate, a breakthrough in treating genetic diseases. The study's discovery provides new avenues for therapies to combat conditions like leukemia.
A new trial shows that chemotherapy plus radiotherapy, either with or without surgery, are viable options for patients with stage IIIA (N2) non-small-cell lung cancer. The treatment improved overall survival and progression-free survival rates compared to standard concurrent chemotherapy and radiotherapy alone.
A study by MU researchers found that cancer survivors experience mild decreases in skills like verbal fluency and problem-solving ability, impacting their daily lives. The researchers identified specific interventions, such as pharmaceuticals and cognitive behavior techniques, to help patients manage these challenges.
A new chemotherapy regimen, ABVE-PC, has been identified as a successful treatment for pediatric Hodgkin lymphoma, reducing long-term risks and improving survival rates. The treatment delivers dose-dense drug delivery while minimizing cumulative doses, resulting in lower toxicity and improved outcomes.
Scientists at Stanford University School of Medicine have created fluorescent probes that can noninvasively image apoptosis in living tumors, allowing for the gauge of treatment effectiveness. The probes bind exclusively to caspases, enzymes regulating cell death, and respond with light emission, highlighting dying cells.
A study by Columbia University's Mailman School of Public Health found that elderly women with localized breast cancer are less likely to receive chemotherapy, with only 15% receiving treatment. In contrast, younger women with nonmetastatic breast cancer received adjuvant chemotherapy at a rate of 70%.
A new study from the University of Michigan Comprehensive Cancer Center found that a single round of chemotherapy can identify patients most likely to benefit from preserving their speech. After three years, 78% of T4 study participants were still alive and 58% had an intact larynx.
Survival rates for placental-site trophoblastic tumours (PSTTs) vary depending on how long ago the related pregnancy occurred. The study found that patients with stage I disease had a 10-year probability of overall survival of 90%, while those with recurrent disease or disease resistant to treatment had poor survival.
The report emphasizes the importance of identifying specific types of breast cancer and tailoring treatment to individual patients. It recommends adjuvant endocrine therapy for most patients with oestrogen receptor-positive tumours, anti-HER2 therapy for HER2-positive disease, and chemotherapy for triple-negative disease.
Researchers design a minimally invasive system combining ultrasound and chemotherapy to target brain tumors without surgery or radiation. The approach aims to provide real-time imaging and localized temperature increases to melt liposome shells and release chemotherapy directly to the tumor.
UCF researcher J. Manuel Perez's nanoparticles could potentially replace chemotherapy with targeted cancer treatment. The nanoparticles, carrying Taxol and other molecules, selectively target cancer cells while leaving healthy tissue intact.
Researchers found that applying a chemotherapy medication to the face reduced actinic keratoses by 87% and improved signs of aging. The treatment also showed promise in addressing photo-aging, with patients reporting improved skin appearance and willingness to undergo therapy again.
A study from Northwestern University found that Cremophor-based paclitaxel caused life-threatening allergic reactions in 38% of patients, leading to 109 deaths. The solvent is believed to trigger severe reactions, even in patients with premedication.
Researchers identified a way to boost cisplatin's effectiveness by targeting DNA repair proteins in cancer cells. Attenuating the function of RAD50 protein complex sensitizes human tumor cells to cisplatin-based chemotherapy.
The I-SPY trial offers critical insights into locally advanced breast cancer, emphasizing the importance of not ignoring growing breast masses. The study found that most interval cancers are discovered between routine mammogram exams, suggesting a need for better screening strategies.
Researchers found that adding gefinitib to standard chemotherapy improved tolerability in advanced head and neck cancer patients, but did not increase survival rates. The combination therapy showed potential in delaying the spread of the disease.
Researchers at the University of Michigan have developed a new understanding of how chromosomes separate during mitosis, a crucial process in cell division. By manipulating chromosome size and observing its effect on movement, they validated the theory that polar ejection forces play a central role in guiding chromosome movements.
A new study reveals that combining chemotherapy agents with 5FU increases disease-free survival for patients under 70, but does not provide similar benefits for those aged 70 and older. The research found that the aggressive treatment strategy is better tolerated by younger patients, while older patients may experience more side effects.
A national survey reveals that nearly all oncologists and ID specialists are highly concerned about the negative impact of infection on treatment outcomes in chemotherapy patients. Infections among chemotherapy patients are common, with one in four patients experiencing an infection in the last 12 months.
AT-101, a cottonseed-derived compound, has shown promise in treating glioblastoma multiforme by halting the growth of tumor cells. The treatment, which must be properly dosed and monitored, has been effective in slowing cancer progression in many patients, offering new hope for those with this aggressive form of brain cancer.
The shift towards oral chemotherapy agents poses risks of non-adherence, which can lead to increased healthcare costs and reduced efficacy. Studies show that non-adherence is often linked to financial constraints, education issues, and side effects, highlighting the need for innovative strategies to improve patient compliance.
Researchers at Boston University School of Medicine found that conventional methods to adjust for confounding, such as restriction and multivariable regression, leave residual confounding because of unmeasured factors. Propensity scores and instrumental variable methods have limitations in resolving confounding by indication.
Research from Northwestern University found Abraxane effectively prevents metastatic breast cancer progression and has fewer side effects compared to Taxotere. The study prolonged progression-free survival by almost seven months.
Researchers at Northwestern University have developed a Nanofountain Probe that can precisely deliver tiny doses of drug-carrying nanomaterials to individual cells. The tool enables targeted cancer treatments and improves drug delivery by reducing side effects and increasing targeting accuracy.
Researchers at the Mayo Clinic have found a triple drug combination to be an effective and tolerable option for treating metastatic HER2+ breast cancer. The regimen, which combines capecitabine, vinorelbine, and trastuzumab, has shown promising results in reducing tumor size and improving survival rates compared to traditional treatments.
A Phase II/III study found that ginger supplements, taken three days prior to and after chemotherapy, reduced nausea levels in cancer patients by 40%. The study included 644 participants who received at least three chemotherapy treatments and showed significant anti-vomiting effects.
A study found that 45% of older women with early-stage breast cancer choose chemotherapy, higher than the national average. The researchers suggest that these women are weighing risks and benefits more thoroughly, making informed decisions about their treatment.
A study by M. D. Anderson Cancer Center researchers found that over one-third of metastatic breast cancer patients receive chemotherapy off-label, with 34.9% of women treated with an unapproved drug at some point during their care. The most common off-label chemotherapies noted were vinorelbine and gemcitabine, both shown to be efficac...
A recent study found that chemotherapy in addition to surgery or radiation improves survival rates among older women with early-stage breast cancer. Combination therapy showed significantly better outcomes than single-drug treatment, with a 17% higher relapse-free survival rate at three years.
A Phase III trial found that adding casopitant mesylate to a conventional two-drug regimen significantly reduced chemotherapy-induced nausea and vomiting events. The study showed that 86% of patients achieved complete response with the new regimen compared to 66% with the placebo.
A phase III study found that adding cetuximab to standard chemotherapy for non-small-cell lung cancer (NSCLC) extends survival by almost one month compared to chemotherapy alone. The treatment has been shown to target epidermal growth factor receptor, which plays a key role in tumour growth.
A study at Duke University Medical Center has led to the development of a new technique that uses light scattering to determine whether chemotherapy is working. The method, called angle-resolved low coherence interferometry, measures changes in cellular structure following treatment with chemotherapeutic agents.
Researchers found hypofractionated stereotactic radiotherapy improved symptoms and survival time in patients with recurrent low-grade glioma. The treatment was well-tolerated and allowed patients to complete the full course of therapy.
A new combination of chemotherapy drugs, topotecan and docetaxel, has produced clinical benefit for patients with recurrent gynecologic cancers. The treatment showed an unusually high proportion of women experiencing clinical benefit, with a median survival time of 18.5 months.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a non-invasive method to determine whether chemotherapy is working after a single treatment cycle, allowing oncologists to discontinue ineffective treatments sooner. This breakthrough enables faster decision-making and potentially improves patient outcomes.
Researchers at NC State University have discovered that a molecule found in soy, genistein, can inhibit the growth of canine lymphoma cells. The study's findings suggest that this compound could be used to enhance traditional cancer treatments like chemotherapy, leading to reduced stress and costs for dog owners.